News
Public · Published
KIDS: Record growth and positive free cash flow; raised FY26 revenue outlook as launches build
Q3 revenue reached a record $72.7M, up 19%, with adjusted EBITDA of $6.9M and positive free cash flow. FY26 revenue guidance rose to $270M–$273M as early product launches and strong OPSB momentum support growth, with broader Super Cycle impact expected from 2027.
Published:
Updated:
What happened
Q3 revenue reached a record $72.7M, up 19%, with adjusted EBITDA of $6.9M and positive free cash flow. FY26 revenue guidance rose to $270M–$273M as early product launches and strong OPSB momentum support growth, with broader Super Cycle impact expected from 2027.
Confirmed
Global impact / market context
Higher revenue guidance means management expects more sales than previously forecast, which can raise future profit expectations if costs stay controlled. Positive free cash flow, the cash left after running and investing in the business, gives the company more room to fund launches without relying on borrowed money.
Analyst inference
This is a growth update from a medical device company, not a broad market signal. Record sales, positive free cash flow and a raised outlook can support investor confidence, but the expected 2027 Super Cycle benefit is future-dependent and not yet confirmed in reported results.
Analyst inference
What to watch
- Watch whether FY26 revenue lands within the raised $270M–$273M guidance range, since that range is now the company's stated expectation. Confirmed
- Track early product launches and OPSB momentum, which the article cites as growth support, to see whether they translate into sustained sales gains. Proposed
- Monitor whether adjusted EBITDA and free cash flow stay positive as sales grow, because rising costs or launch spending could absorb the benefit of higher revenue. Analyst inference
Evidence
- Original source link unavailable